Form 4: Elutia Chief Scientific Officer Reports Routine Stock Transactions Following RSU Vesting
Insider Transaction Report
Elutia Inc.'s Chief Scientific Officer, Michelle LeRoux Williams, reported the scheduled vesting of 12,500 restricted stock units and the subsequent acquisition of Class A Common Stock, with a portion withheld for tax obligations.
Summary
- Michelle LeRoux Williams, Chief Scientific Officer of Elutia Inc. (ELUT), reported transactions related to her equity holdings.
- On June 10, 2025, 12,500 restricted stock units (RSUs) vested, resulting in the acquisition of 12,500 shares of Class A Common Stock.
- Concurrently, 3,951 shares of Class A Common Stock were disposed of (withheld by the Issuer) to satisfy tax withholding requirements at a price of $1.99 per share.
- Following these transactions, Ms. Williams beneficially owns 84,835 shares of Class A Common Stock directly.
- Additionally, Ms. Williams beneficially owns 75,000 derivative securities in the form of restricted stock units.
- The RSUs were part of a grant of 150,000 units on January 31, 2024, with a vesting schedule that includes 1/6 vesting on June 10, 2024, and 1/12 vesting quarterly thereafter until December 10, 2026.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of executive stock transactions related to RSU vesting, which is a pre-scheduled compensation event and does not inherently indicate positive or negative company performance or significant new information beyond the expected.
Positives
- The vesting of restricted stock units represents a scheduled compensation event, indicating the company's commitment to executive retention and alignment of interests through equity ownership.
- The acquisition of shares through RSU vesting increases the direct equity stake of a key executive, potentially signaling confidence in the company's long-term prospects.
Negatives
- A portion of the vested shares (3,951 shares) was withheld by the issuer to cover tax obligations, which is a standard practice but reduces the immediate net share gain for the executive.
Future Outlook
The document outlines a clear future vesting schedule for the remaining 75,000 restricted stock units held by the Chief Scientific Officer, with quarterly vesting events continuing until December 10, 2026. This indicates a continued alignment of executive incentives with long-term company performance.
Industry Context
This Form 4 filing is a standard regulatory disclosure for publicly traded companies, detailing changes in beneficial ownership by company insiders. Such filings are common across all industries as part of executive compensation plans involving equity awards like restricted stock units, which are designed to incentivize long-term performance and retention.
Stakeholder Impact
- Shareholders: The vesting and subsequent acquisition of shares by a key executive can be viewed positively as it aligns management's interests with shareholder value. The withholding of shares for tax purposes is a standard, non-dilutive event for existing shareholders.
Next Steps
- Continued quarterly vesting of the remaining 75,000 restricted stock units held by the Chief Scientific Officer until December 10, 2026.
Key Dates
| Date | Description |
|---|---|
| 01/31/2024 | Date when 150,000 restricted stock units were granted to the Reporting Person. |
| 06/10/2024 | First vesting date for 1/6 of the granted restricted stock units. |
| 09/10/2024 | Scheduled quarterly vesting date for 1/12 of the granted restricted stock units. |
| 12/10/2024 | Scheduled quarterly vesting date for 1/12 of the granted restricted stock units. |
| 03/10/2025 | Scheduled quarterly vesting date for 1/12 of the granted restricted stock units. |
| 06/10/2025 | Transaction date for the reported RSU vesting and stock acquisition/disposition. |
| 09/10/2025 | Scheduled quarterly vesting date for 1/12 of the granted restricted stock units. |
| 12/10/2025 | Scheduled quarterly vesting date for 1/12 of the granted restricted stock units. |
| 03/10/2026 | Scheduled quarterly vesting date for 1/12 of the granted restricted stock units. |
| 06/10/2026 | Scheduled quarterly vesting date for 1/12 of the granted restricted stock units. |
| 09/10/2026 | Scheduled quarterly vesting date for 1/12 of the granted restricted stock units. |
| 12/10/2026 | Final scheduled quarterly vesting date for 1/12 of the granted restricted stock units. |
| 06/12/2025 | Date the Form 4 filing was signed. |
Keywords
Elutia Inc., ELUT, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Ownership, Chief Scientific Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.